Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond
Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.
Artificial intelligence company Hologen AI has committed up to $430 million as part of a multifaceted agreement to help take MeiraGTx’s Parkinson’s disease gene therapy all the way to market.
